{"id":41177,"date":"2023-11-20T00:46:06","date_gmt":"2023-11-20T06:46:06","guid":{"rendered":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/acrin-dsc-mr-brain-pub\/"},"modified":"2023-11-20T00:46:06","modified_gmt":"2023-11-20T06:46:06","slug":"acrin-dsc-mr-brain-pub","status":"publish","type":"tcia_citation","link":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/acrin-dsc-mr-brain-pub\/","title":{"rendered":"ACRIN-DSC-MR-BRAIN-PUB"},"template":"","class_list":["post-41177","tcia_citation","type-tcia_citation","status-publish"],"tcia_citation_type":"Publication Citation","tcia_citation_text":"<p>Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. (2013) <strong>Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677\/RTOG 0625 Central Reader Study<\/strong>. Neuro Oncol. 15:945-954. DOI: <a href=\"https:\/\/doi.org\/10.1093\/neuonc\/not049\">10.1093\/neuonc\/not049<\/a>.<\/p>\n","tcia_citation_statement":"","tcia_citation_doi":"10.1093\/neuonc\/not049","_links":{"self":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations\/41177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations"}],"about":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/types\/tcia_citation"}],"wp:attachment":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/media?parent=41177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}